Ex Parte Naber et al - Page 16



                Appeal 2006-2468                                                                             
                Application 10/149,875                                                                       

                Seiden discloses a reduced calorie fat composition having weight percent                     
                ranges for the amount of PFAP (about 10 to about 95, preferably about 35 to                  
                about 95, and most preferably about 65 to about 95) and the amount of RCT                    
                (about 5 to about 90, preferably about 5 to about 65, and most preferably                    
                about 5 to about 35).  The most preferred ranges of these components                         
                encompass and substantially overlap the range amounts for those                              
                components as required by the respective representative claims without                       
                significantly deviating therefrom.  See, e.g., column 10, lines 50-56 and                    
                column 12, lines 10-16 of Seiden.  In this regard, representative claim 1                    
                requires about 65 to about 80 weight percent PFAP and about 20 to about 35                   
                weight percent RCT in the fat composition.  Representative claim 3 requires                  
                a fat composition with about 70 to about 80 weight percent PFAP and about                    
                20 to about 30 weight percent RCT therein.                                                   
                      Thus, the description of the preferred ranges of amounts for PFAP and                  
                RCT of about 65 to 95 weight percent and about 5 to about 35 weight                          
                percent, respectively, in Seiden anticipate the ranges recited in the                        
                representative claims because the prior art ranges entirely or substantially                 
                encompass and do not significantly deviate from the Appellants’ claimed                      
                ranges.  Perricone v. Medicis Pharmaceutical Corp., 432 F.3d 1368,                           
                1377 U.S.P.Q.2d 1321, 1327 (Fed. Cir. 2005).                                                 
                      Appellants discuss Perricone and Atofina v. Great Lakes Chem.                          
                Corp., 441 F.3d 991, 78 U.S.P.Q.2d 1417, (Fed. Cir. 2006) in a                               
                Supplemental Appeal Brief filed May 05, 2006 in response to a March 31,                      

                                                        16                                                   




Page:  Previous  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  Next 

Last modified: November 3, 2007